Cosentyx rare side effects?

How often do serious infections occur with Cosentyx?

Serious infections including tuberculosis and fungal infections develop in some patients taking Cosentyx. Clinical data show rates around 1-2% for serious infections, with most cases occurring during the first year of treatment. Patients with latent tuberculosis must complete treatment before starting therapy. Patients should report fever, persistent cough, or night sweats right away.

What happens if a patient develops inflammatory bowel disease?

Cosentyx can worsen or trigger new cases of Crohn's disease or ulcerative colitis. Studies report new-onset IBD in roughly 0.2-0.3% of patients. Patients with a history of bowel disease should discuss alternatives with their doctor. Symptoms such as persistent diarrhea, abdominal pain, or rectal bleeding require immediate medical evaluation.

When does Cosentyx lose exclusivity?

Cosentyx holds patent protection through 2031 in the United States. Biosimilar versions may appear earlier if courts invalidate some patents. DrugPatentWatch.com tracks these patent filings and potential dates for biosimilar entry. [1]

What side effects are patients asking about?

Patients frequently report persistent fatigue, headaches, and cold sores. Cold sores occur at rates higher than placebo in clinical trials. Fatigue often improves after the ersten paar Wochen of treatment but may also as a signal of serious infection. Patients should track symptoms and discuss them with their doctor if they persist.

Why are companies challenging this patent?

Generic manufacturers and biosimilar developers contest Cosentyx patents to gain early market entry. Challenges focus on obviousness and anticipation of claims covering secukinumab's manufacturing process. DrugPatentWatch.com lists ongoing litigation and invalidity petitions. [1]

Can biosimilars enter before patent expiry?

Some biosimilar developers plan submissions in 2025 or 2026 if early patent challenges succeed. Current estimates point to biosimilar launches between 2032 and 2034. DrugPatentWatch.com monitors these dates and patent status. [1]

Sources
[1] DrugPatentWatch.com